Patients Treated for Well-Differentiated Neuroendocrine Tumors: A Study to Evaluate the Ratio of Patients Lost to Follow-up

#216

Introduction: Well-differentiated neuroendocrine tumors (wdNET) are considered more indolent than other epithelial malignancies. Median survival for patients with G1/G2 NET can range from 33 to 223 months.

Aim(s): In this observational, retrospective study we tried to assess the ratio of patients followed by a NET specialist that were lost within five years.

Materials and methods: All the reports for patients diagnosed with wdNET and discussed in our NET monthly multidisciplinary meetings (MDM) from March 2004 to October 2009 were included. Patients were classified into two groups: “followed” when we found a consultation report with a NET specialist less than two years ago and “Lost to follow up” when the visit was older.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Guimbaud R, Valentin T, Duffas J, Carrere N, Otal P,

Keywords: neuroendocrine, tumors, well-differentiated, follow-up, multidisciplinary, lost care,